Streetbeat News

CLOV

Clover Health Investments, Corp.

https://www.cloverhealth.com

Industry

Medical - Healthcare Plans

Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.

Open

3.65

Mkt cap

1.9B

Volume

3.3M

High

3.73

P/E Ratio

-40.89

52-wk high

4.87

Low

3.56

Div yield

N/A

52-wk low

0.61

Clover Health announces Clay Thornton as the new CFO of its Medicare Advantage division. Thornton, with a strong background in healthcare financial management and operational leadership, aims to drive the company towards Adjusted EBITDA profitability by 2024. His experience includes significant roles at Humana Inc., and his expertise is expected to bolster Clover's PPO-first product strategy and use of technology in managed care.

Portfolio Pulse from Happy Mohamed

March 07, 2024 | 9:26 pm

Clover Health, a healthcare company, has announced its target to achieve adjusted EBITDA profitability for the fiscal year 2024. This forward-looking statement indicates the company's focus on improving its financial health and operational efficiency.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 1:33 pm

Clover Health Investments has announced the departure of its CFO, Scott Leffler, effective January 26, 2024. The company has not yet named a successor.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 1:09 pm

Clover Health Investments, Corp. (NASDAQ:CLOV) shares have experienced volatility throughout November, with a rally in early November ahead of its Q3 earnings report. The company reported sales of $482.07 million, missing estimates, and an earnings loss of nine cents per share, beating expectations. Despite an initial drop post-earnings, CLOV shares rose 11.1% to $1.00, potentially influenced by positive October CPI data indicating easing U.S. inflation.

Portfolio Pulse from Ryan Gustafson

November 14, 2023 | 8:25 pm

Clover Health's shares are trading lower following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 6:12 pm

The article lists the stocks that gained and lost the most in Tuesday's mid-day session. Among the gainers were PaxMedica, Senti Biosciences, Tharimmune, TransMedics Group, and Singular Genomics Systems. Among the losers were Ventyx Biosciences, Alto Ingredients, Worldwide Webb Acquisition Corp, Oportun Financial Corporation, and Royalty Management Holding Corporation.

Portfolio Pulse from Lisa Levin

November 07, 2023 | 6:10 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Gainers included PaxMedica (PXMD), Senti Biosciences (SNTI), Cardio Diagnostics Hldgs (CDIO), TransMedics Gr (TMDX), Korro Bio (KRRO), and Tharimmune (THAR). Losers included Ventyx Biosciences (VTYX), Aura Biosciences (AURA), MSP Recovery (LIFW), Coherus BioSciences (CHRS), Clover Health Investments (CLOV), and Tactile Systems Tech (TCMD). Q3 earnings reports were recently released for TMDX, CHRS, CLOV, and TCMD.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 5:31 pm

Clover Health Investments Corp (NASDAQ:CLOV) reported Q3 revenue of $482.07 million, missing the consensus estimate of $494.6 million. Insurance revenues were up 12% YoY to $301.2 million. The company reported an adjusted EBITDA loss of $5.1 million, improved from a loss of $55.5 million YoY. Clover Health revised its 2023 adjusted EBITDA outlook from a loss of $70 million to $120 million to a loss of $55 million to $80 million. The company updated its full-year 2023 insurance revenue outlook from a range of $1.2 to $1.23 billion to a new range of $1.21 to $1.23 billion.

Portfolio Pulse from Adam Eckert

November 07, 2023 | 2:28 pm

Several stocks are experiencing significant pre-market movements. Senti Biosciences, Tharimmune, TransMedics Group, GSE Systems, Unisys Corporation, Alteryx, Augmedix, Color Star Technology, CF Acquisition Corp. IV, and Tripadvisor reported gains due to various reasons such as strategic collaborations, licensing agreements, better-than-expected Q3 results, and strong FY23 revenue guidance. On the other hand, Ventyx Biosciences, Alto Ingredients, MSP Recovery, Coherus BioSciences, Ameresco, Aura Biosciences, Clover Health Investments, Trevena, Tenon Medical, and NanoString Technologies reported losses due to reasons such as disappointing trial results, mixed Q3 results, and weak quarterly sales.

Portfolio Pulse from Lisa Levin

November 07, 2023 | 1:28 pm

In Tuesday's pre-market session, several health care stocks saw significant movement. Senti Biosciences, Tharimmune, TransMedics Gr, Synlogic, Advanced Health, and Augmedix saw increases, with Senti Biosciences leading with a 139.8% increase. On the other hand, Ventyx Biosciences, Aura Biosciences, Coherus BioSciences, MSP Recovery, Clover Health Investments, and Trevena saw decreases, with Ventyx Biosciences falling the most by 76.2%.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.